Benepali® is a biosimilar of the TNF-α inhibitor Etanercept (Enbrel®) for the treatment of patients with rheumatoid arthritis, psoriatic arthritis, axial spondylitis and plaque psoriasis.
Rapid Review
Commenced | Completed | Outcome |
22/03/2016 | 10/05/2016 | Full Pharmacoeconomic Evaluation not Recommended |